NDAORALTABLET
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
SOTYKTU (deucravacitinib) by Bristol Myers Squibb is tyrosine kinase 2 inhibitors [moa]. Approved for plaque psoriasis. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOTYKTU (deucravacitinib) is an oral tyrosine kinase 2 (TK2) inhibitor developed by Bristol Myers Squibb and approved by the FDA on September 9, 2022. It represents a novel mechanism of action targeting TK2, a key signaling protein in immune regulation. The drug is indicated for treating inflammatory and immune-mediated conditions where TK2 inhibition provides therapeutic benefit. As a first-in-class TK2 inhibitor, SOTYKTU occupies a unique position in the immunology treatment landscape.
$0.0BPart D
16.8 years to LOEMechanism of Action
Tyrosine Kinase 2 Inhibitors
Pharmacologic Class:
Tyrosine Kinase 2 Inhibitor
Indications (1)
Clinical Trials (20)
Deucravacitinib in the Treatment of Cicatricial Alopecias
Started Apr 2026
20 enrolled
Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Started Feb 2026
35 enrolled
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Started Dec 2025
366 enrolled
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Started Aug 2025
200 enrolled
Psoriasis
Worked on SOTYKTU at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.